SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated…
DOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical…
LOUISVILLE, Ky., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a national leader in musculoskeletal (MSK) care, today announced its…
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy…
Late breaking session to feature results from the successful PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract…
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®…
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the…
Award recognizes technology breakthroughs that promise to help define the future of their industriesNEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE)…
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone…
Notification has no immediate effect on the Company’s listing or day-to-day operationsROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone…